Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Crinetics Pharmaceuticals presented up to two years of data from PATHFNDR-1 and PATHFNDR-2 open-label extension studies showing that PALSONIFY (paltusotine), an oral somatostatin receptor agonist, maintains stable IGF-1 levels, controls acromegaly symptoms, and stabilizes or reduces pituitary tumor volume. The data confirmed durable disease control…